Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 11/20 | 0.65 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.50 |
| ▸ | FLT4 | P35916 | 1/20 | 0.49 |
| ▸ | BTK | Q06187 | 1/20 | 0.49 |
| ▸ | MELK | Q14680 | 1/20 | 0.49 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 2/20 | 0.48 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.48 |
| ▸ | RAF1 | P04049 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3977510 | 0.90 | BRAF (0.66) | BRAFBLMEPHB4FLT4KDR | |
| SCHEMBL4199752 | 0.87 | BRAF (0.82) | BRAFKDRMAPK14MAPT | |
| SCHEMBL4198556 | 0.86 | CNR1 (0.62) | BRAFBLMMAPT | |
| SCHEMBL4188384 | 0.85 | BRAF (0.63) | BRAFKDRMAPT | |
| SCHEMBL4195622 | 0.84 | BRAF (0.59) | BRAFBLMEPHB4FLT4BTK | |
| SCHEMBL4188391 | 0.82 | BRAF (0.61) | BRAFBLMFLT4MELKKDR | |
| SCHEMBL4198743 | 0.80 | BRAF (0.72) | BRAFMAPK14MAPT | |
| SCHEMBL3978525 | 0.79 | BRAF (1.00) | BRAFKDRMAPT | |
| SCHEMBL4195978 | 0.78 | BRAF (0.76) | BRAFKDR | |
| SCHEMBL12684804 | 0.76 | BLM (0.58) | BRAFBLMEPHB4KDRMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118276-A1 | THIENOPYRIMIDINES, THIENOPYRIDINES, AND PYRROLOPYRIMIDINES AS B-RAF INHIBITORS | WYETH (US) | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118276-A1 | THIENOPYRIMIDINES, THIENOPYRIDINES, AND PYRROLOPYRIMIDINES AS B-RAF INHIBITORS | BRAF, ARAF, RAF1 | BRAF 1/4885BLM 2054/4885EPHB4 1457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.